Tvardi Therapeutics (TVRD) Stock Price, News & Analysis

Company Overview

Cara Therapeutics, Inc., an early commercial-stage biopharmaceutical company, focuses on developing and commercializing chemical entities with a primary focus on pruritus and pain by selectively targeting kappa opioid receptors in the United States. The company is developing product candidates that target the body's peripheral nervous system and immune cells. The company's lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis. Its product candidate includes Oral KORSUVA (difelikefalin), which has completed Phase II clinical trial to treat pruritus atopic dermatitis and pruritus non-dialysis-dependent chronic kidney disease (NDD-CKD) associated pruritus; and in Phase II clinical trial to treat pruritus chronic liver disease (CLD) primary biliary cholangitis (PBC) and notalgia paresthetica. The company has license agreements with Maruishi Pharmaceutical Co., Ltd to develop, manufacture, and commercialize drug products containing difelikefalin for acute pain and uremic pruritus in Japan; and Chong Kun Dang Pharmaceutical Corporation to develop, manufacture, and commercialize drug products containing difelikefalin in South Korea. Cara Therapeutics, Inc. was incorporated in 2004 and is based in Stamford, Connecticut.

Key Stats

• Today's Range: $1.79 to $1.89
• 50-Day Range: $1.50 to $5.00
• 52-Week Range: $1.50 to $43.65
• Volume: 77,064 shs
• Average Volume: 272,054 shs
• Market Capitalization: $24.28 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $18.00
• Consensus Rating: Moderate Buy

Tvardi Therapeutics Stock Analysis - MarketRank™

Tvardi Therapeutics scored higher than 71% of companies evaluated by MarketBeat, and ranked 178th out of 917 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.4 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Tvardi Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.78, and is based on 1 strong buy rating, 6 buy ratings, 1 hold rating, and 1 sell rating.

Upside Potential

Tvardi Therapeutics has a consensus price target of $18.00, representing about 889.0% upside from its current price of $1.82.

Amount of Analyst Coverage

Tvardi Therapeutics has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Tvardi Therapeutics are expected to decrease in the coming year, from ($2.35) to ($2.78) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Tvardi Therapeutics is -0.65, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Tvardi Therapeutics is -0.65, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Tvardi Therapeutics has a P/B Ratio of 2.89. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

1.40% of the float of Tvardi Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Tvardi Therapeutics has a short interest ratio ("days to cover") of 0.64, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Tvardi Therapeutics has recently decreased by 33.97%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Tvardi Therapeutics does not currently pay a dividend.

Dividend Growth

Tvardi Therapeutics does not have a long track record of dividend growth.

News and Social Media

• Score: 2.3 / 5
• News Sentiment: 0.71

News Sentiment

Tvardi Therapeutics has a news sentiment score of 0.71. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 4 news articles for Tvardi Therapeutics this week, compared to 2 articles on an average week.

Search Interest

Only 1 people have searched for TVRD on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

MarketBeat Follows

Only 1 people have added Tvardi Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days.

Company Ownership

• Score: 0.8 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Tvardi Therapeutics insiders have not sold or bought any company stock.

Percentage Held by Insiders

7.40% of the stock of Tvardi Therapeutics is held by insiders.

Percentage Held by Institutions

44.66% of the stock of Tvardi Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 8/14/2026
• Today: 8/25/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Pharmaceuticals
• Sub-Industry: Pharmaceuticals
• Current Symbol: NASDAQ:TVRD
• Previous Symbol: NASDAQ:TVRD
• CIK: 1346830
• Web: caratherapeutics.com
• Phone: (203) 406-3700
• Fax: 203-567-1510
• Employees: 80
• Year Founded: 2004

Price Target and Rating

• Average Price Target for Tvardi Therapeutics: $18.00
• High Price Target: $61.00
• Low Price Target: $5.00
• Potential Upside/Downside: +889.0%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.78
• Research Coverage: 9 Analysts

Profitability

• EPS (Trailing Twelve Months): ($2.79)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$18.21 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -145.40%
• Return on Assets: -91.11%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 1.87
• Quick Ratio: 1.87

Sales & Book Value

• Annual Sales: $7.14 million
• Price / Sales: 3.40
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.63 per share
• Price / Book: 2.89

Miscellaneous

• Outstanding Shares: 13,340,000
• Free Float: 12,352,000
• Market Cap: $24.28 million
• Optionable: N/A
• Beta: 0.39